Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: A multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer

Gastric Cancer

Volumn 14, Issue 1, 2011, Pages 81-90

  Imamoto, Haruhiko ^a   Oba, Koji ^b   Sakamoto, Junichi ^c   Iishi, Hiroyasu ^d   Narahara, Hiroyuki ^e   Yumiba, Takeyoshi ^f   Morimoto, Takashi ^g   Nakamura, Masaki ^h   Oriuchi, Noboru ⁱ   Kakutani, Chieko ^j   Morita, Satoshi ^k   Shiozaki, Hitoshi ^a  

^a KINKI UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^e HIROSHIMA UNIVERSITY   (Japan)

^f OSAKA KOSEI NENKIN HOSPITAL   (Japan)

^g Yao Municipal Hospital   (Japan)

^h WAKAYAMA MEDICAL UNIVERSITY   (Japan)

ⁱ GUNMA UNIVERSITY   (Japan)

^j KYOTO UNIVERSITY   (Japan)

^k YOKOHAMA CITY UNIVERSITY   (Japan)

more..

Author keywords

Clinical benefit response in gastric cancer (CBR GC); Five point method (5PM); Gastric cancer; Malignant ascites; Paclitaxel

Indexed keywords

PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASCITES TUMOR; CANCER PATIENT; CANCER SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT CANCER; STOMACH ADENOCARCINOMA; STOMACH CANCER; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASCITES; ASCITIC FLUID; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

EID: 79953028953     PISSN: 14363291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10120-011-0016-6     Document Type: Article

References (37)

1. Mathers C. Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3:442. World Health Organization, Geneva. http://www.who.int/healthinfo/statistics/bod-projections2030-paper.pdf.
2. B Glimelius K Hoffman U Haglund O Nyrén PO Sjödén 1994 Initial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189 190 8186165 1:STN:280:DyaK2c3kt1KrsA%3D%3D (Pubitemid 24062577)
3. AM Murad FF Santiago A Petroianu PR Rocha MA Rodrigues M Rausch 1993 Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer. 72 37 41 8508427 10.1002/1097-0142(19930701)72:1<37:: AID-CNCR2820720109>3.0.CO;2-P 1:STN:280:DyaK3s3osVGqtQ%3D%3D (Pubitemid 23182046)
4. S Pyrhönen T Kuitunen P Nyandoto M Kouri 1995 Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587 591 7533517 10.1038/bjc.1995.114
5. A Ohtsu N Boku F Tamura K Muro Y Shimada K Saigenji, et al. 1998 A phaseII study of a 3-hour infusion of paclitaxel for advanced gastric cancer Am J Clin Oncol 21 416 9708646 10.1097/00000421-199808000-00021 1:STN:280:DyaK1cznt1emsw%3D%3D (Pubitemid 28366916)
6. Y Kodera S Ito Y Mochizuki S Fujitake K Koshikawa Y Kanyama T Matsui H Kojima T Takase N Ohashi M Fujiwara J Sakamoto N Akimasa Chubu Clinical Cancer Group 2007 A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study) Anticancer Res 27 2667 2671 17695430 1:CAS:528:DC%2BD2sXpvFChsbY%3D (Pubitemid 47227980)
7. Y Emi M Yamamoto I Takahashi H Orita Y Kakeji S Kohnoe Y Maehara 2008 Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer Surg Today 38 1013 1020 18958560 10.1007/s00595-008-3769-8 1:CAS:528:DC%2BD1cXht12rtrnF
8. PH Wiernik EL Schwartz JJ Strauman JP Dutcher RB Lipton E Paietta 1987 Phase 1 clinical and pharmacokinetic study of Taxol Cancer Res 47 2486 2493 2882837 1:STN:280:DyaL2s7oslansw%3D%3D (Pubitemid 17099218)
9. M Kobayashi J Sakamoto T Namikawa K Okamoto T Okabayashi K Ichikawa K Araki 2006 Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients World J Gastroenterol 12 1412 1415 16552811 1:CAS:528:DC%2BD28XksVynur8%3D
10. M Kobayashi K Oba J Sakamoto K Kondo N Nagata T Okabayashi T Namikawa K Hanazaki 2007 Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan Gastric Cancer 10 52 57 17334719 10.1007/s10120-006-0411-6 1:CAS:528:DC%2BD2sXisVejurc%3D (Pubitemid 46357474)
11. ML Rothenberg MJ Moore MC Cripps JS Andersen RK Portenoy HA Burris 3rd MR Green PG Tarassoff TD Brown ES Casper AM Storniolo DD Von Hoff 1996 A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer Ann Oncol 7 4 347 353 8805925 1:STN:280:DyaK28zpvFCgsA%3D%3D (Pubitemid 26246785)
12. HA Burris 3rd MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff 1997 Improvements in survival, clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 6 2403 2413 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D (Pubitemid 27251144)
13. H Burris AM Storniolo 1997 Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil Eur J Cancer 33 818 10.1016/S0959-8049(97)90092-7 (Pubitemid 27288576)
14. J Sakamoto S Morita T Yumiba H Narahara K Kinoshita Y Nakane H Imamoto H Shiozaki 2003 Ascitic Gastric Cancer Study Group of the Japan South West Oncology Group. A phase II clinical trial to evaluate the effect of paclitaxel in patients with ascites caused by advanced or recurrent gastric carcinoma: a new concept of clinical benefit response for non-measurable type of gastric cancer Jpn J Clin Oncol 33 238 240 12865468 10.1093/jjco/hyg048 1:CAS:528:DC%2BD2cXlt1ajsLo%3D (Pubitemid 43115265)
15. N Oriuchi T Nakajima E Mochiki I Takeyoshi T Kanuma K Endo J Sakamoto 2005 A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients Jpn J Clin Oncol 35 386 390 15976067 10.1093/jjco/hyi109 (Pubitemid 41418696)
16. SY Oh HC Kwon S Lee DM Lee HS Yoo SH Kim JS Jang MC Kim JS Jeong HJ Kim 2007 A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites Jpn J Clin Oncol 37 930 935 18211984 10.1093/jjco/hym131 (Pubitemid 351176484)
17. G Piccoli S Smania F Toso L Borghese R Pozzi Mucelli M Vergendo, et al. 2004 Multislice CT anatomy of hepatic artery in patients undergoing liver transplantation using 3D reconstructions Radiol Med 108 372 379 15525890 (Pubitemid 39487006)
18. P Ohorodnyk EA Eisenhauer CM Booth 2009 Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point? Eur J Cancer 45 13 2249 2252 19545996 10.1016/j.ejca.2009.05.033
19. Y Yonemura T Fujimura S Fushida S Takegawa T Kamata K Katayama T Kosaka A Yamaguchi K Miwa I Miyazaki 1991 Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination World J Surg 15 530 536 1891941 10.1007/BF01675656 1:STN:280:DyaK3MzmvVGntg%3D%3D
20. S Fujimoto RD Shrestha M Kokubun M Ohta M Takahashi K Kobayashi S Kiuchi K Okui T Miyoshi N Arimizu 1988 Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding Ann Surg 208 36 41 3133994 10.1097/00000658-198807000-00005 1:STN:280: DyaL1c3mvVaqtg%3D%3D
21. O Glehen V Schreiber E Cotte AC Sayag-Beaujard D Osinsky G Freyer Y François J Vignal FN Gilly 2004 Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer Arch Surg 139 1 20 26 14718269 10.1001/archsurg.139.1.20 1:STN:280: DC%2BD2c%2FitVKqtg%3D%3D (Pubitemid 38049613)
22. E Facchiano S Scaringi R Kianmanesh JM Sabate B Castel Y Flamant B Coffin S Msika 2008 Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer Eur J Surg Oncol 34 2 154 158 17640844 1:STN:280:DC%2BD1c%2FltVemtA%3D%3D Epub 2007 Jul 20
23. SG Arbuck F Trave HO Douglass Jr H Nava S Zakrzewski YM Rustum 1986 Phase I and pharmacologic studies of intraperitoneal leucovorin and 5-fluorouracil in patients with advanced cancer J Clin Oncol 4 1510 1517 3489819 1:STN:280:DyaL2s%2FhtVOlsg%3D%3D (Pubitemid 17183576)
24. Y Inaba Y Arai K Matsueda T Aramaki Y Kodera 2003 Intractable massive ascites following radical gastrectomy, treatment with local intraperitoneal administration of OK-432 using a unified CT and fluoroscopy system Australas Radiol 47 465 467 14641206 10.1046/j.1440-1673.2003.01223.x (Pubitemid 38082979)
25. HR Rosen G Jatzko S Repse S Potrc H Neudorfer P Sandbichler J Zacherl H Rabl P Holzberger P Lisborg M Czeijka 1998 Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology J Clin Oncol 16 2733 2738 9704725 1:CAS:528:DyaK1cXlsFCgu7w%3D (Pubitemid 28363038)
26. N Nakayama W Koizumi S Tanabe T Sasaki K Saigenji 2006 A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501) Gastric Cancer 9 185 191 16952036 10.1007/s10120-006-0371-x 1:CAS:528:DC%2BD28XptVeqsrw%3D
27. T Oshima R Yamada S Hatori C Kunisaki T Imada 2006 Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer Oncol Rep 16 361 366 16820916 1:CAS:528:DC%2BD28XptFWgu74%3D
28. K Ishido W Koizumi S Tanabe K Higuchi T Sasaki C Katada M Azuma K Saigenji N Futawatari M Saegusa 2008 A patient with stage IV type 4 advanced gastric cancer who had a complete pathological response to short-term treatment with S-1 alone Anticancer Drugs 19 921 925 18766007 10.1097/CAD.0b013e32830d58a6 1:CAS:528:DC%2BD1cXhtVGktLzK
29. J Sakamoto T Matsui Y Kodera 2009 Paclitaxel chemotherapy for the treatment of gastric cancer Gastric Cancer 12 69 78 19562460 10.1007/s10120-009-0505-z 1:CAS:528:DC%2BD1MXnvVWqsrY%3D
30. VL Seewaldt BE Greer JM Cain DC Figge HK Tamimi WS Brown SA Miller 1994 Paclitaxel (Taxol) treatment for refractory ovarian cancer: phase 2 clinical trial Am J Obstet Gynecol 170 1666 1671 7911273 1:STN:280:DyaK2c3mt1Klsg%3D%3D (Pubitemid 24202470)
31. A Du Bois HJ Lück K Buser HG Meerpohl C Sessa U Klaassen H Meden H Bochtler K Diergarten 1997 Extended phase 2 study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum Eur J Cancer 33 379 384 9155520 10.1016/S0959-8049(97)89009-0 1:CAS:528: DyaK2sXislagurw%3D (Pubitemid 27168062)
32. JP Guastalla C Lhommé J Dauplat M Namer J Bonneterre F Oberling P Pouillart P Fumoleau P Kerbrat N Tubiana 1994 Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase 2 multicenter study Ann Oncol 5 S33 S38 7865432
33. DJ Vaughn SB Malkowicz B Zoltick R Mick P Ramchandani C Holroyde B Armstead K Fox A Wein 1998 Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen J Clin Oncol 16 255 260 9440750 1:CAS:528:DyaK1cXmsVGqsg%3D%3D (Pubitemid 28041606)
34. S Hironaka S Zenda N Boku A Fukutomi T Yoshino Y Onozawa 2006 Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer Gastric Cancer 9 14 18 16557431 10.1007/s10120-005-0351-6 1:CAS:528: DC%2BD28XivVeguro%3D
35. M Sebastian A Kuemmel M Schmidt A Schmittel 2009 Catumaxomab: a bispecific trifunctional antibody Drugs Today (Barc) 45 589 597 10.1358/dot.2009.45.8.1401103 1:STN:280:DC%2BD1MjntVKgug%3D%3D
36. F Lordick K Ott J Weitz D Jäger 2008 The evolving role of catumaxomab in gastric cancer Expert Opin Biol Ther 8 1407 1415 18694358 10.1517/14712598.8.9.1407 1:CAS:528:DC%2BD1cXpslartro%3D
37. T Yamao Y Shimada K Shirao A Ohtsu N Ikeda I Hyodo H Saito H Iwase Y Tsuji T Tamura S Yamamoto S Yoshida 2004 Phase II study of sequential methotrexate and 5-fluorouracil chemotherapy against peritoneally disseminated gastric cancer with malignant ascites: a report from the Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group, JCOG 9603 Trial Jpn J Clin Oncol 34 316 322 15333683 10.1093/jjco/hyh063 (Pubitemid 43118050)